Clinical Trial Update: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) [Phase 2]

View source ↗

Summary

Phase 2 RESCUE trial evaluating SHR-1210 (anti-PD-1) in combination with Apatinib for advanced hepatocellular carcinoma has completed and results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-02-17